Given the similar mechanisms of action (preventing PD‐1 and PD‐L1 interaction) and similar safety and efficacy profiles in patients with Child‐Pugh A cirrhosis, it is reasonable to expect similar safety and efficacy of durvalumab as has been observed with nivolumab in patients with Child‐Pugh B cirrhosis. Here, CD274 is linked to Cirrhosis.